This study focuses on patients with acute heart failure, a condition where the heart cannot pump blood effectively, leading to symptoms like shortness of breath, fatigue, and fluid buildup in the body. The study will test a medication called dapagliflozin, given as a film-coated tablet, compared to a placebo. The purpose is to determine if starting this medication during hospital stay can improve outcomes for patients who have been stabilized after being admitted for acute heart failure.

The medication or placebo will be taken by mouth once daily for two months. Cardiovascular health and heart failure symptoms will be monitored throughout the study period. This includes tracking any heart-related deaths or worsening of heart failure symptoms that might require additional treatment or hospital readmission.

The study will involve patients who have different levels of heart function, as measured by left ventricular ejection fraction (the amount of blood pumped out by the heart’s main chamber). Both patients with and without type 2 diabetes can participate in the study. The medication will only be started after patients have shown initial improvement with standard hospital treatment for their heart failure.